tiprankstipranks
EMA Reviews Pfizer-BioNTech COVID Vaccine Booster for Adolescents — Report
Market News

EMA Reviews Pfizer-BioNTech COVID Vaccine Booster for Adolescents — Report

According to a report published by Reuters, the European Medicines Agency (EMA) is evaluating whether the COVID-19 vaccine of Pfizer, Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) can be administered to adolescents aged between 12 and 15 as a third booster dose.

Several countries in the European Union (EU) have already started giving the companies’ vaccine as a third booster shot to adolescents.

“Advice on how vaccinations should be given remains the prerogative of (EU) member states’ advisory groups,” the EMA said.

The agency is also reviewing whether the vaccine can be given to teenagers aged 16 and 17.

Separately, the European Centre for Disease Prevention and Control (ECDC) said, “Findings so far suggest an increase of vaccine effectiveness against infection in adolescents who received a booster compared to adolescents who have recently completed the primary vaccination course.”

It also said that 10 nations in the European Economic Area have already recommended that those aged less than 18 years should take a booster dose of the vaccine.

About Pfizer

New York-based Pfizer develops, manufactures and sells healthcare products, including medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, and internal medicine.

The company’s shares closed 2.8% lower on Tuesday. They were trading 0.4% down in the pre-market session on Wednesday at the time of writing.

Analysts’ Take

Following the release of Pfizer’s fourth-quarter results, Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating and $75 price target (45.1% upside potential) on the stock.

Additionally, Vamil Divan of Mizuho Securities maintained a Hold rating on Pfizer with a price target of $56 (8.3% upside potential).

Overall, the stock has a Moderate Buy consensus rating based on 9 Buys and 9 Holds. The average Pfizer stock price prediction of $60.13 implies 16.3% upside potential. Shares have gained 49.3% over the past year.

Hedge Fund Trading Activity

TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Pfizer is currently Very Positive, as the cumulative change in holdings across all 26 hedge funds that were active in the last quarter was an increase of 4.4 million shares.

Download the TipRanks mobile app now.

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Read full Disclaimer & Disclosure

Related News:
Novavax Delays COVID-19 Vaccine Deliveries — Report
Understanding Tesla’s Risk Factors
Doximity Jumps Over 8% on Upbeat Q3 Results

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles